A Dana-Farber review found that 26% of carboplatin rationing decisions during the 2023 shortage did not match policy. What it means for cancer patients.
One in Four Carboplatin Rationing Decisions at Dana-Farber Did Not Match Its Own Policy During the 2023 Shortage
by | Oct 20, 2026 | Uncategorized | 0 comments
Recent Comments